David Luke Fischer, M.D., Ph.D.
|2006-2010||Radiology, Neurology||Michigan State University, East Lansing, MI|
|2010-2018||Translational Science and Molecular Medicine||Michigan State University, East Lansing, MI|
|2018-||Neurology||University of Alabama, Birmingham, Birmingham, AL, United States|
Area:Parkinson's disease, deep brain stimulation, brain-derived neurotrophic factor
Google:"D. Luke Fischer"
D. Luke Fischer is a neuroscientist specializing in Parkinson's disease research. He graduated Phi Beta Kappa from Michigan State University with degrees in Philosophy and Biochemistry & Molecular Biology, and he remained there to complete his PhD in Neuroscience in the laboratory of Dr. Caryl E. Sortwell as part of a dual-MD/PhD program. As a trainee in the NINDS Morris K. Udall Center of Excellence for Parkinson's Disease Research at Michigan State University, his focus was on the use of deep brain stimulation in rodent models of Parkinson's disease to investigate its potential as a neuroprotective therapy. He remained in her laboratory as a postdoctoral fellow to examine the impact of common genetic variants on clinical outcomes for developing precision medicine approaches for treating patients with Parkinson's disease. Luke is currently in the neurology residency program at the University of Alabama at Birmingham.
Mean distance: 18.69 (cluster 19)
ParentsSign in to add mentor
ChildrenSign in to add trainee
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.
|Fischer DL, Gombash SE, Kemp CJ, et al. (2016) Viral Vector-Based Modeling of Neurodegenerative Disorders: Parkinson's Disease. Methods in Molecular Biology (Clifton, N.J.). 1382: 367-82|
|Fischer DL, Collier TJ, Cole-Strauss A, et al. (2015) High-Frequency Stimulation of the Rat Entopeduncular Nucleus Does Not Provide Functional or Morphological Neuroprotection from 6-Hydroxydopamine. Plos One. 10: e0133957|
|Gombash SE, Manfredsson FP, Mandel RJ, et al. (2014) Neuroprotective potential of pleiotrophin overexpression in the striatonigral pathway compared with overexpression in both the striatonigral and nigrostriatal pathways. Gene Therapy. 21: 682-93|